Longitudinal bone growth occurs in the growth plate through a process in which resting zone chondrocytes are recruited to start active proliferation and then undergo differentiation, followed by apoptosis and later mineralization. Bone growth is controlled by a multitude of genes encoding for hormones and growth factors acting systemically and/or locally in the growth plate. From studies of individuals with a mutated aromatase gene and a male patient with defective oestrogen receptor (ER) α, it has become clear that the action of oestrogen is indispensable for normal pubertal growth and growth plate fusion. As new aromatase inhibitors and specific modulators of ERs are developed, these could offer more specific ways to modulate longitudinal growth and growth plate fusion. It is difficult to extrapolate data obtained in experimental animals, as clear species differences exist, emphasizing the need for new models that will allow studies in human growth plate cartilage.

Keywords:
Cartilage, Chondrocyte, Genes, Growth plate, Oestrogen
1.
Abad V, Meyers JL, Weise M, Gafni RI, Barnes KM, Nilsson O, Bacher JD, Baron J: The role of the resting zone in growth plate chondrogenesis. Endocrinology 2002;143:1851–1857.
2.
Kember NF: Cell kinetics and the control of growth in long bones. Cell Tissue Kinet 1978;11:477–485.
3.
Kember NF, Walker KV: Control of bone growth in rats. Nature 1971;229:428–429.
4.
Baron J, Klein KO, Yanovski JA, Novosad JA, Bacher JD, Bolander ME, Cutler GB Jr: Induction of growth plate cartilage ossification by basic fibroblast growth factor. Endocrinology 1994;135:2790–2793.
5.
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623–628.
6.
Haeusler G, Walter I, Helmreich M, Egerbacher M: Localization of matrix metalloproteinases, (MMPs) their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation. Calcif Tissue Int 2005;76:326–335.
7.
Farnum CE, Wilsman NJ: Morphologic stages of the terminal hypertrophic chondrocyte of growth plate cartilage. Anat Rec 1987;219:221–232.
8.
Gibson G: Active role of chondrocyte apoptosis in endochondral ossification. Microsc Res Tech 1998;43:191–204.
9.
Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061.
10.
Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689–3698.
11.
Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599–603.
12.
Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91–95.
13.
Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C: Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004;89:61–70.
14.
Goldzieher MA: Treatment of excessive growth in the adolescent female. J Clin Endocrinol Metab 1956;16:249–252.
15.
Conte FA, Grumbach MM: Estrogen use in children and adolescents: a survey. Pediatrics 1978;62:1091–1097.
16.
Barnard ND, Scialli AR, Bobela S: The current use of estrogens for growth-suppressant therapy in adolescent girls. J Pediatr Adolesc Gynecol 2002;15:23–26.
17.
Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743–1748.
18.
Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396–6402.
19.
McDonnell DP: The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999;10:301–311.
20.
Barrett-Connor E: Raloxifene: risks and benefits. Ann NY Acad Sci 2001;949:295–303.
21.
McDonnell DP, Norris JD: Connections and regulation of the human estrogen receptor. Science 2002;296:1642–1644.
22.
McKenna NJ, O’Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465–474.
23.
Riggs BL, Hartmann LC: Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618–629.
24.
Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247–263.
25.
Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH: Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003;143:60–66.
26.
Eugster EA, Shankar R, Feezle LK, Pescovitz OH: Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab 1999;12:681–686.
27.
Kreher NC, Eugster EA, Shankar RR: The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics 2005;116:1513–1515.
28.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML: Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004;145:71–76.
29.
Nilsson O, Falk J, Ritzen EM, Baron J, Savendahl L: Raloxifene acts as an estrogen agonist on the rabbit growth plate. Endocrinology 2003;144:1481–1485.
30.
Metzger DL, Kerrigan JR: Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. J Clin Endocrinol Metab 1994;79:513–518.
31.
Laron Z, Lilos P, Klinger B: Growth curves for Laron syndrome. Arch Dis Child 1993;68:768–770.
32.
Attie KM, Ramirez NR, Conte FA, Kaplan SL, Grumbach MM: The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids. J Clin Endocrinol Metab 1990;71:975–983.
33.
Vanderschueren D, Boonen S, Ederveen AG, de Coster R, Van Herck E, Moermans K, Vandenput L, Verstuyf A, Bouillon R: Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone 2000;27:611–617.
34.
Danielsen CC, Flyvbjerg A: Insulin-like growth factor I as a predictor of cortical bone mass in a long-term study of ovariectomized and estrogen-treated rats. Bone 1996;19:493–498.
35.
Tivesten A, Moverare-Skrtic S, Chagin A, Venken K, Salmon P, Vanderschueren D, Savendahl L, Holmang A, Ohlsson C: Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res 2004;19:1833–1839.
36.
Eshet R, Maor G, Ben Ari T, Ben Eliezer M, Gat-Yablonski G, Phillip M: The aromatase inhibitor letrozole increases epiphyseal growth plate height and tibial length in peripubertal male mice. J Endocrinol 2004;182:165–172.
37.
Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson JA, Ohlsson C: Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 2000;97:5474–5479.
38.
Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C: Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol 2001;171:229–236.
39.
Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96:7088–7092.
40.
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324–7329.
41.
Cutler GB Jr: The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997;61:141–144.
42.
Klein KO, Martha PM Jr, Blizzard RM, Herbst T, Rogol AD: A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay. J Clin Endocrinol Metab 1996;81:3203–3207.
43.
Walker QD, Francis R, Cabassa J, Kuhn CM: Effect of ovarian hormones and estrous cycle on stimulation of the hypothalamo-pituitary-adrenal axis by cocaine. J Pharmacol Exp Ther 2001;297:291–298.
44.
Sahlin L, Elger W, Akerberg S, Masironi B, Reddersen G, Schneider B, Schwarz S, Freyschuss B, Eriksson H: Effects of estradiol and estradiol sulfamate on the uterus of ovariectomized or ovariectomized and hypophysectomized rats. J Steroid Biochem Mol Biol 2000;74:99–107.
45.
Nilsson O, Abad V, Chrysis D, Ritzen EM, Savendahl L, Baron J: Estrogen receptor- alpha and -beta are expressed throughout postnatal development in the rat and rabbit growth plate. J Endocrinol 2002;173:407–414.
46.
Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J: Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001;98:6871–6876.
47.
Kusec V, Virdi AS, Prince R, Triffitt JT: Localization of estrogen receptor-alpha in human and rabbit skeletal tissues. J Clin Endocrinol Metab 1998;83:2421–2428.
48.
Nilsson LO, Boman A, Savendahl L, Grigelioniene G, Ohlsson C, Ritzen EM, Wroblewski J: Demonstration of estrogen receptor-beta immunoreactivity in human growth plate cartilage. J Clin Endocrinol Metab 1999;84:370–373.
49.
Nilsson O, Chrysis D, Pajulo O, Boman A, Holst M, Rubinstein J, Martin Ritzen E, Savendahl L: Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages. J Endocrinol 2003;177:319–326.
50.
Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625–1630.
51.
Chagin AS, Savendahl L: GPR30 estrogen receptor expression in the growth plate declines as puberty progresses. J Clin Endocrinol Metab 2007;92:4873–4877.
52.
Blanchard O, Tsagris L, Rappaport R, Duval-Beaupere G, Corvol M: Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991;40:711–716.
53.
Jansson JO, Eden S, Isaksson O: Sites of action of testosterone and estradiol on longitudinal bone growth. Am J Physiol 1983;244:E135–E140.
54.
Gevers EF, Wit JM, Robinson IC: Effect of gonadectomy on growth and GH responsiveness in dwarf rats. J Endocrinol 1995;145:69–79.
55.
Sibonga JD, Dobnig H, Harden RM, Turner RT: Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998;139:3736–3742.
56.
Maor G, Segev Y, Phillip M: Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle – a model of endochondral ossification. Endocrinology 1999;140:1901–1910.
57.
Somjen D, Weisman Y, Harell A, Berger E, Kaye AM: Direct and sex-specific stimulation by sex steroids of creatine kinase activity and DNA synthesis in rat bone. Proc Natl Acad Sci USA 1989;86:3361–3365.
58.
Somjen D, Weisman Y, Mor Z, Harell A, Kaye AM: Regulation of proliferation of rat cartilage and bone by sex steroid hormones. J Steroid Biochem Mol Biol 1991;40:717–723.
59.
Nasatzky E, Schwartz Z, Boyan BD, Soskolne WA, Ornoy A: Sex-dependent effects of 17-beta-estradiol on chondrocyte differentiation in culture. J Cell Physiol 1993;154:359–367.
60.
Schwartz Z, Finer Y, Nasatzky E, Soskolne WA, Dean DD, Boyan BD, Ornoy A: The effects of 17 beta-estradiol on chondrocyte differentiation are modulated by vitamin D3 metabolites. Endocrine 1997;7:209–218.
61.
Rodd C, Jourdain N, Alini M: Action of estradiol on epiphyseal growth plate chondrocytes. Calcif Tissue Int 2004;75:214–224.
62.
Chagin AS, Chrysis D, Takigawa M, Ritzen EM, Savendahl L: Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J Endocrinol 2006;188:193–203.
63.
Perry RJ, Farquharson C, Ahmed SF: Estrogen action at the level of the growth plate. Horm Res 2006;65(suppl 4):27.
64.
Sylvia VL, Gay I, Hardin R, Dean DD, Boyan BD, Schwartz Z: Rat costochondral chondrocytes produce 17beta-estradiol and regulate its production by 1alpha,25(OH)(2)D(3). Bone 2002;30:57–63.
65.
Van Der Eerden BC, Van De Ven J, Lowik CW, Wit JM, Karperien M: Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology 2002;143:4048–4055.
66.
Labrie C, Belanger A, Labrie F: Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412–1417.
67.
Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152–182.
68.
Simpson ER: Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225–230.
69.
Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD: Estrogen – the good, the bad, and the unexpected. Endocr Rev 2005;26:322–330.
70.
Oz OK, Millsaps R, Welch R, Birch J, Zerwekh JE: Expression of aromatase in the human growth plate. J Mol Endocrinol 2001;27:249–253.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.